Related by context. All words. (Click for frequent words.) 77 dose cohort 74 dose regimens 73 dosing cohorts 72 dosing cohort 72 Phase 2a trial 72 ascending doses 71 placebo controlled Phase 71 evaluable subjects 71 ascending dose 70 mg kg dose 70 mg/m2 dose 70 forodesine 70 dose escalation trial 70 dosage regimens 70 Phase 2b trial 70 dosing regimens 70 Phase 1b 69 evaluable patients 69 elotuzumab 69 teriflunomide 69 docetaxel chemotherapy 69 Phase Ib 68 Phase 2b study 68 phase IIb clinical 68 viral kinetic 68 dose escalation 68 Phase Ib II 68 Phase 1b trial 68 Amrubicin 68 HGS ETR1 68 Traficet EN 68 phase Ib 68 low dose cytarabine 68 phase IIb trial 67 APTIVUS r 67 relapsed refractory multiple myeloma 67 Phase Ib study 67 nab paclitaxel 67 mg dose 67 rindopepimut 67 mcg kg 67 pomalidomide 67 relapsed MM 67 heavily pretreated 67 Bezielle 67 heavily pretreated patients 67 chlorambucil 67 phase IIa clinical 67 bicifadine 66 Phase 2a 66 dose escalation Phase 66 CIMZIA TM 66 Phase IIa trial 66 double blinded placebo 66 patients evaluable 66 μg dose 66 dose dexamethasone 66 mg BID 66 axitinib 66 HGS# 66 TMC# r 66 placebo controlled clinical trials 66 subcutaneous doses 66 blinded randomized placebo controlled 66 #mg/m# [001] 66 mg QD 66 galiximab 66 mapatumumab 66 EVIZON 66 azacitidine 66 Phase Ib clinical 66 decitabine 66 dose dose escalation 66 PEG PAL 65 secondary efficacy endpoints 65 placebo controlled Phase III 65 mg doses 65 phase IIb 65 INCB# [001] 65 ponatinib 65 ongoing Phase 1b 65 alvespimycin 65 HCV SPRINT 65 dose cytarabine 65 Phase IIb trials 65 IMGN# 65 ganetespib 65 cilengitide 65 tanespimycin 65 active comparator 65 HCV genotypes 65 RRMS patients 65 SCH # 65 posaconazole 65 FOLPI 65 CANCIDAS 65 EOquin TM 65 vicriviroc 65 rapid virologic response 65 Tarceva TM 65 glufosfamide 65 LEXIVA r 65 phase IIb study 65 tolerated dose MTD 65 pharmacokinetics PK 65 dose limiting toxicities 65 celgosivir 65 evaluable 65 HCD# [002] 65 oral ridaforolimus 65 multicenter Phase III 65 neratinib 65 Phase IIIb clinical 65 APTIVUS 65 Sym# 65 #mg/m# [002] 65 systemic ALCL 65 crizotinib PF # 65 adalimumab 64 IMC A# 64 bendamustine 64 certolizumab 64 ritonavir boosted 64 BRIM3 64 sunitinib malate 64 mCi kg 64 oral rivaroxaban 64 metastatic CRC 64 dose escalation phase 64 refractory CLL 64 phase IIa 64 CLARITY study 64 docetaxel Taxotere R 64 Phase IIa trials 64 HGS ETR2 64 intravenous dosing 64 MGd 64 enzastaurin 64 dosing schedules 64 mRCC 64 pertuzumab 64 lintuzumab SGN 64 treatment naive genotype 64 administered subcutaneously 64 remission CR 64 pharmacodynamic 64 HCV RESPOND 2 64 pharmacokinetic PK 64 PRECiSE 64 valopicitabine 64 Phase 1b clinical 64 docetaxel Taxotere ® 64 PEG Interferon lambda 64 MGCD# [001] 64 pegylated interferon alpha 64 HER2 positive metastatic breast 64 huN# DM1 64 #mg dose [002] 64 multiple ascending dose 64 plus dexamethasone 64 desvenlafaxine succinate 64 CR# vcMMAE 64 budesonide foam 64 eniluracil 64 prior chemotherapy regimens 64 Phase 2b clinical 64 CAMMS# 64 placebo controlled clinical 64 FOLFIRI 64 standard chemotherapy regimen 64 mcg dose 64 RESIST studies 63 carboplatin paclitaxel 63 PROMACTA 63 lintuzumab 63 Phase 1a 63 PREZISTA r 63 Phase III placebo controlled 63 fosbretabulin 63 RSD# oral 63 dose escalation study 63 PF # [001] 63 TELCYTA 63 monotherapy 63 mg RDEA# 63 PEG IFN 63 leukemia AML 63 partial remissions 63 vandetanib 63 evaluating tivozanib 63 KRAS mutations occur 63 phase 2a 63 virologic failure 63 INCB# [002] 63 inhibitor RG# 63 intermittent dosing 63 CLORETAZINE TM VNP#M 63 safety tolerability pharmacokinetics 63 subcutaneous formulation 63 Allovectin 7 ® 63 dose melphalan 63 diabetic neuropathic pain 63 indolent NHL 63 Dacogen injection 63 receptor tyrosine kinase inhibitor 63 anti leukemic 63 Phase #/#a 63 MabCampath 63 placebo controlled studies 63 dexamethasone Decadron 63 randomized controlled Phase 63 MAGE A3 ASCI 63 CYT# 63 multicenter Phase 63 Pegasys ® 63 dose cyclophosphamide 63 registrational 63 riociguat 63 perampanel 63 GAMMAGARD 63 Pegasys plus Copegus 63 liver metastases 63 Ozarelix 63 antitumor activity 63 Phase 2b 63 PEGylated interferon beta 1a 63 plasma uric acid 63 GVAX 63 #mg QD [002] 63 DAPT 63 fluvastatin 63 Phase 1a clinical 63 Azedra 63 Panzem R NCD 63 doxorubicin docetaxel 63 rilonacept 63 eculizumab 63 randomized Phase III 63 Aurexis 63 superficial bladder cancer 63 AEGR 63 FAME Study 63 dose regimen 63 treatment naïve genotype 63 metastatic renal cell carcinoma 63 R# #mg BID 63 tolerability 63 dosing intervals 63 Phase IIa clinical trials 63 sapacitabine 63 NP2 Enkephalin 63 lesinurad 63 mg/m2/day 63 randomized Phase 63 SCIg 63 Actilon 63 docetaxel 63 dosed orally 63 q#h 63 dose escalation clinical 63 nitazoxanide 63 IV bolus 63 BAY #-# 63 Chemophase 62 antiviral efficacy 62 BRIM2 62 plus ribavirin 62 dirucotide 62 RDEA# 62 Folfox 62 alfa 2a 62 clinical trials SGN 62 metastatic HRPC 62 RG# [001] 62 GSK# [001] 62 mipomersen 62 mcg doses 62 AQ4N 62 CIMZIA ™ 62 grade glioma 62 Neulasta ® 62 brivaracetam 62 dasatinib 62 multicenter Phase II 62 REYATAZ r arm 62 ABSORB trial 62 Fludara 62 subcutaneous injections 62 rNAPc2 62 atazanavir ritonavir 62 ELACYT 62 teduglutide 62 pivotal Phase III 62 AP# [003] 62 PRT# 62 YONDELIS 62 mitomycin 62 ISENTRESS 62 timepoints 62 Phase IIa clinical 62 GRN#L 62 ancrod 62 PXD# 62 complete remissions 62 Phase #b/#a 62 XL# [003] 62 #mg BID [003] 62 NATRECOR R 62 ANCHOR trial 62 PSMA ADC 62 pharmacokinetic profile 62 afatinib 62 AEG# 62 fluticasone furoate 62 viral kinetics 62 SAR# [004] 62 amrubicin 62 angiographic outcomes 62 TMC# [001] 62 pegylated interferon alfa 2a 62 multicenter randomized placebo controlled 62 Seliciclib 62 registrational trial 62 lumiliximab 62 DLTs 62 prospectively defined 62 TELINTRA 62 doxorubicin cyclophosphamide 62 peginterferon alfa 2b 62 mg/m2 62 ENDEAVOR II 62 Alocrest 62 Phase 2b randomized 62 #mg dose [001] 62 EndoTAG TM -1 62 mcg BID 62 mycophenolate mofetil 62 Ophena TM 62 apremilast 62 OMP #M# 62 Phase IIb 62 relapsed multiple myeloma 62 thymalfasin 62 pharmacodynamic PD 62 Cloretazine R VNP#M 62 EOquin 62 immunomodulatory therapy 62 subcutaneous SC 62 subcutaneously administered 62 rALLy clinical trial 62 #mg QD [001] 62 gemcitabine carboplatin 62 undetectable HBV DNA 62 4mg/kg 62 ularitide 62 Phase IIIb 62 TRIOLEX 62 albinterferon alfa 2b 62 sunitinib 62 belinostat 62 mg m² 62 CoFactor 62 null responders 62 velafermin 62 Omacetaxine 62 HspE7 62 gout flares 62 dacetuzumab 62 ISIS # 62 mg ustekinumab 62 Pivotal Phase III 62 TG# [003] 62 nucleotide analog 62 multicenter placebo controlled 62 splenectomized patients 62 Engerix B 62 ALGRX 62 mcg albinterferon alfa 2b 62 MIRCERA 62 antibody titers 61 elagolix 61 NO# [002] 61 insulin degludec 61 CHOP chemotherapy 61 telaprevir dosing 61 mg/m2 cohort 61 recurrent GBM 61 ACTEMRA TM 61 NOX E# 61 HBV DNA levels 61 docetaxel Taxotere 61 #mg dose [003] 61 Pegasys peginterferon alfa 2a 61 blind randomized placebo 61 eltrombopag 61 mg administered orally 61 pharmacodynamics 61 intradermal injections 61 AZT zidovudine Retrovir 61 Telintra 61 continuous intravenous infusion 61 huC# DM4 61 trabedersen 61 virological failure 61 PRTX 61 Phase III trials 61 SUTENT 61 protease inhibitor PI 61 recurrent glioblastoma multiforme 61 PRADAXA 61 BARACLUDE ® 61 pivotal Phase 61 dirucotide MBP# 61 virologic response 61 pegfilgrastim 61 ofatumumab 61 CRp 61 octreotide LAR 61 investigational monoclonal antibody 61 fosamprenavir 61 q#d 61 metaglidasen 61 CLL SLL 61 PegIFN RBV 61 melphalan prednisone 61 Cotara 61 Phase IIb trial 61 timepoint 61 sorafenib Nexavar ® 61 Carfilzomib 61 Phase III Clinical Trials 61 Phase IIa 61 orally administered inhibitor 61 hA# 61 oral FTY# 61 clinical pharmacology studies 61 pharmacokinetic parameters 61 Phase #/#a trial 61 cytogenetic response 61 Tyrima 61 dacarbazine 61 elacytarabine 61 T DM1 61 ACAPODENE 61 IMA# 61 randomized #:# 61 Aptivus ® 61 multicenter randomized double 61 OncoVEX GM CSF 61 refractory AML 61 Phase III clinical trials 61 adecatumumab 61 Phase 2a clinical 61 lopinavir r 61 piperacillin tazobactam 61 micafungin 61 NLX P# 61 randomized Phase 2b 61 Phase IIb clinical trials 61 edoxaban 61 pharmacokinetic characteristics 61 TMC# C# 61 dasatinib Sprycel ® 61 composite endpoint 61 safety tolerability pharmacokinetic 61 CUSTOM III 61 xenograft models 61 Cethromycin 61 #mg BID [001] 61 pharmacokinetic profiles 61 Peg IFN 61 trials RCTs 61 microgram doses 61 LY# [003] 61 BRAF inhibitor 61 imatinib therapy 61 Apoptone 61 nilotinib 61 double blinded randomized 61 recurrent glioma 61 Laquinimod 61 lomitapide 61 rFIXFc 61 glatiramer acetate 61 PS# [001] 61 tolvaptan 61 temsirolimus 61 tezampanel 61 Afatinib 61 rHuPH# 61 randomized multicenter Phase III 61 R#/MEM # 61 events SAEs 61 baminercept 61 histologies 61 Tamibarotene 61 PSN# [002] 61 evaluating Xcytrin 61 mg kg cohorts 61 ixabepilone 61 odanacatib 61 plus methotrexate 61 MYCAMINE 61 Phase III clinical 61 CCX# 61 Xelox 61 pegylated interferon 61 Cladribine Tablets 61 tipranavir r 61 refractory CTCL 61 Doxil ® 61 placebo controlled 61 8mg/kg 61 sustained virologic response 61 budesonide MMX 61 YERVOY 61 events AEs 61 ara C 61 randomized Phase IIb 61 placebo controlled randomized 61 grade cervical intraepithelial 61 canakinumab 61 PEG SN# 61 paclitaxel eluting stents 61 follicular NHL 61 FOLPI regimen 61 CCyR 61 darunavir ritonavir 61 Flu Cy 61 IFN α 61 BR.# 61 endoscopic remission 61 pharmacodynamics PD 61 boosted protease inhibitor 61 visilizumab 61 complete cytogenetic 61 randomized placebo controlled 60 MDV# 60 efavirenz EFV 60 rFVIIa 60 rilpivirine 60 Phase III randomized controlled 60 VELCADE melphalan 60 cannabinor 60 DermaVir Patch 60 efficacy endpoint 60 ruxolitinib 60 investigational protease inhibitor 60 CEQ# 60 pharmacodynamic profile 60 interferon alfa 60 imetelstat 60 Blinatumomab 60 Pharmacokinetics PK 60 refractory multiple myeloma 60 IDX# 60 tocilizumab 60 ILLUMINATE 60 SPIRIT FIRST 60 taxane resistant 60 orally bioavailable 60 oblimersen 60 prucalopride 60 relapsing remitting multiple sclerosis 60 MERLIN TIMI 60 eosinophilic asthma 60 oral prodrug 60 IIIa inhibitor 60 pharmacokinetic studies 60 cell lymphoma CTCL 60 protein kinase inhibitor 60 TORISEL 60 ARCOXIA 60 XIENCE V PROMUS Stent 60 definite stent thrombosis 60 HBeAg positive patients 60 pan HDAC inhibitor 60 goserelin 60 null responder HCV 60 Asentar 60 rALLy 60 placebo intravenously 60 TMC# [002] 60 randomized blinded 60 REMICADE ® 60 maximally tolerated dose 60 blinatumomab 60 AZILECT R 60 alemtuzumab treated 60 intravenously administered 60 tigecycline 60 oral allopurinol 60 subcutaneous PRO 60 nucleoside analog 60 oral deforolimus 60 mg q8h 60 bolus dose 60 Lupuzor ™ 60 tolerability profile 60 serum urate 60 BENICAR HCT 60 Elagolix 60 estramustine 60 veltuzumab 60 PRIMO CABG 60 KRN# 60 PASI scores 60 Phase III randomized 60 Taxotere ® 60 LEP ETU 60 CHAMPION PCI 60 ZD# [001] 60 refractory NSCLC 60 TREANDA 60 ribavirin therapy 60 octreotide 60 HBeAg positive 60 stated Michelle Berrey 60 INCB# [003] 60 Phase IIb clinical 60 hematologic toxicity 60 irbesartan 60 label dose escalation 60 TACI Ig 60 Dose escalation 60 Elitek 60 microgram kg 60 DAVANAT 60 pharmacokinetic PK study 60 sorafenib Nexavar 60 pharmacokinetic 60 telaprevir dosed 60 HuMax CD4 60 mg qd 60 NVA# 60 lupus nephritis 60 brentuximab vedotin SGN 60 levetiracetam 60 JAK inhibitor 60 RGB # 60 mGluR5 NAM 60 #mg doses [002] 60 PROSTVAC TM 60 Gabapentin GR 60 virological response 60 gemcitabine 60 Zenvia 60 HBeAg seroconversion 60 peg interferon 60 S/GSK# 60 AeroLEF TM 60 ribavirin RBV 60 RE LY ® 60 BMS # 60 RSD# 60 MNTX 60 EURIDIS 60 vidofludimus 60 sitagliptin 60 Viramidine 60 mcg QD 60 neurologic progression 60 randomized multicenter 60 subcutaneous dose 60 EMPHASIS HF trial 60 rt PA 60 peginterferon alfa 2a 60 Phase 2b clinical trials 60 undetectable HCV RNA 60 PMX # 60 triptorelin 60 GRNVAC1 60 bortezomib 60 TBC# 60 ritonavir boosted atazanavir 60 divalproex sodium 60 GALNS 60 RAPTIVA 60 chemotherapeutic regimens 60 ruboxistaurin 60 IIa trial 60 saline placebo 60 relapsed refractory 60 aflibercept 60 tipranavir 60 EFAPROXYN 60 infusional 5-FU/LV 60 assessing T DM1 60 DASISION 60 dose colchicine 60 HuMax EGFr 60 OXi# 60 nonclinical studies 60 Betaferon ® 60 SVR# 60 Phase 1b clinical trials 60 Cloretazine ® 60 insulin detemir 60 Amigal 60 achieved ACR# 60 paclitaxel cisplatin 60 unfractionated heparin UFH 60 MAS XR 60 safety tolerability 60 HRPC 60 liposomal formulation 60 CA4P 60 seroprotection 60 ADVANCE PD 60 paclitaxel Taxol ® 60 Exherin TM 60 dabigatran etexilate 60 gemcitabine cisplatin 60 pegylated liposomal doxorubicin 60 Phase IIB 60 Cloretazine 60 metastatic castration resistant 60 Teriflunomide 60 receiving INTRON 60 mg TID 60 ALT flares 60 LUX Lung 60 demonstrated antitumor activity 60 ABC/3TC 60 intravesical 60 ARB telmisartan 60 IV NSCLC 60 weekly intravenous infusions 60 cediranib 60 seroconversion 60 blinded placebo controlled 60 free survival PFS 60 adalimumab Humira 60 VIDAZA 60 randomized multicenter trial 60 interferon alfa 2b 60 MVax 60 Rebif ® 60 ZOLINZA 60 virus HCV protease inhibitor 60 daunorubicin 60 QUADRAMET 60 REYATAZ r 60 metastatic hormone refractory 60 Dasatinib 60 Omacetaxine mepesuccinate 59 prospective randomized placebo 59 TYKERB 59 lenalidomide dexamethasone 59 CIMZIA TM certolizumab pegol 59 vismodegib 59 grade cervical dysplasia 59 Randomized Phase 59 analgesic efficacy 59 rALLy trial 59 radezolid 59 Tekamlo 59 ARIKACE 59 neoadjuvant chemotherapy 59 GRN# 59 Cimzia ® 59 favorable pharmacokinetic profile 59 complete cytogenetic response 59 lymphocytosis 59 OADs 59 tumor shrinkage 59 olaparib 59 tecarfarin 59 HBeAg negative patients 59 tumor regression 59 SinuNase TM 59 Plicera 59 placebo controlled trials 59 Phase Ia 59 dose proportional pharmacokinetics 59 HCV genotype 1 59 fludarabine 59 Q#IR 59 trastuzumab DM1 59 CRLX# 59 REYATAZ R 59 #I TM# 59 HIV RNA 59 vinorelbine 59 double blind placebo 59 ALKS 59 TNF antagonist 59 Maximum Tolerated Dose 59 carfilzomib 59 panitumumab 59 Perifosine 59 HCV infected 59 azilsartan medoxomil 59 antiviral activity 59 ZACTIMA 59 FTY# 59 #mg/day [001] 59 JANUVIA 59 PreCISe study 59 μg doses 59 Targretin 59 antiretroviral naive 59 FOLFOX4 59 Phase III 59 FOLFOX 59 randomized 59 rosuvastatin #mg 59 peg IFN 59 ZYBRESTAT 59 q8h 59 alvimopan 59 FOLOTYN 59 RECIST criteria 59 iclaprim 59 rizatriptan 59 iniparib 59 CR nPR 59 BCX# 59 achieved sustained virological 59 monoclonal antibody conjugated 59 COPAXONE ® 59 PROSTVAC VF 59 GFT# 59 abiraterone acetate 59 AZOR 59 CYT# potent vascular disrupting 59 erlotinib Tarceva ® 59 FluCAM 59 XL# SAR# 59 clevidipine 59 NXL# 59 oral bioavailability 59 omecamtiv mecarbil 59 seliciclib 59 Xanafide 59 tolerability profiles 59 dosage regimen 59 COMFORT II 59 Vidaza azacitidine 59 mCRC patients 59 achieved PASI 59 severe hypercholesterolemia 59 ISTODAX 59 temozolomide 59 urate lowering 59 ORMD 59 virologic breakthrough 59 febrile neutropenia 59 PEGINTRON TM 59 relapsing multiple sclerosis 59 virologic response EVR 59 raltegravir 59 primary hypercholesterolemia 59 multicentre randomized 59 de novo kidney transplant 59 Jevtana 59 generation purine nucleoside 59 AGILECT R 59 Sapacitabine 59 mg kg hr 59 registrational studies 59 alkylating agent 59 rituximab 59 GetGoal Phase III 59 ARRY 59 dexpramipexole 59 comparator arm 59 relapsed CLL 59 stage IIIB 59 HoFH 59 plasma HCV RNA 59 peginterferon alfa 2a #KD 59 trabectedin 59 zolmitriptan 59 phase III ACCLAIM 59 mixed dyslipidemia 59 metastatic RCC 59 MCyR 59 ZYBRESTAT fosbretabulin 59 EGFR TKI 59 metastatic renal cell 59 MKC# MT 59 INTERCEPT platelets 59 plasma concentrations 59 alefacept 59 eculizumab therapy 59 Aclidinium 59 APOPTONE 59 mTOR inhibitors 59 Brentuximab Vedotin SGN 59 #D#C# 59 motesanib 59 Annamycin 59 Imprime PGG 59 VIRAMUNE XR 59 cytarabine 59 HuMax CD# 59 systemically administered 59 alicaforsen enema 59 evaluating REVLIMID 59 PEGPH# 59 OvaRex ® MAb 59 atacicept 59 biologic DMARD 59 mcg Albuferon 59 dopamine partial agonist 59 intravenous bolus 59 ATACAND 59 severe neutropenia 59 trastuzumab Herceptin R 59 LymphoStat B 59 RLY# 59 venlafaxine ER 59 trastuzumab emtansine T DM1 59 Phase #b/#a clinical 59 Lenocta 59 NRTIs 59 peginterferon 59 pramlintide 59 pharmacodynamic effects 59 Initiated Phase 59 virologic 59 STELARA 59 MAP# 59 Forodesine HCl 59 multicenter clinical 59 PRE SURGE 59 LEXIVA 59 Zevalin R Ibritumomab 59 bortezomib refractory 59 ozarelix 59 recurrent VTE 59 CR CRu 59 plasma kallikrein inhibitor 59 Phase Ib clinical trials 59 oxymorphone ER 59 COPAXONE R 59 Reverset 59 laquinimod 59 atazanavir sulfate 59 serum phosphorus 59 Aflibercept 59 lopinavir r arm 59 abacavir lamivudine 59 QD dosing 59 NATRECOR ® 59 Allovectin 7 R 59 Durezol 59 cytogenetic responses 59 peginterferon alpha 2a 59 darapladib 59 avosentan 59 liposomal doxorubicin 59 Dapagliflozin 59 LPV r 59 Zenvia Phase III 59 relapsed MCL 59 tofacitinib 59 including eniluracil ADH 59 BEACOPP 59 PPAR gamma agonist 59 Locteron 59 OHR/AVR# 59 advanced carcinoid 59 tesmilifene 59 chemoradiotherapy 59 PegIntron 59 otamixaban 59 tesetaxel 59 Golimumab 59 PROSTVAC ® 58 sipuleucel T 58 grade gliomas 58 IEQ kg 58 multicenter trials 58 telbivudine 58 ZYVOX 58 AZD# 58 EDEMA3 58 ATL# [001] 58 Taxotere R 58 aminotransferase elevations greater 58 ceftazidime 58 Lantus ® 58 ibandronate 58 ORENCIA ® 58 serum calcium levels 58 TTF Therapy 58 Bicifadine 58 AZX# 58 GOUT 58 LibiGel Phase III 58 LIALDA 58 Raptiva r 58 intravitreal injection 58 etoposide 58 ACR# response 58 RoACTEMRA 58 Decitabine